![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Arbaclofen is the active enantiomer of baclofen, a GABA-B receptor agonist. Statistically significant and clinically meaningful efficacy was observed in a prior Phase 3 trial conducted by Seaside Therapeutics in humans with Fragile X Syndrome.
Lead Product(s): Baclofen
Therapeutic Area: Genetic Disease Product Name: STX209
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Allos Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 19, 2020